


SUPPLEMENTARY FIGURE



Supplementary Figure S1: FXR agonist CDCA/CDDP co-treatment additively inhibits STAT3-Bcl-xL signaling. **A.** Protein levels of Bcl-xL in GBC-SD and RBE cells treated with CDDP alone, CDCA alone and CDDP/CDCA combination for 36h. **B.** The STAT3 phosphorylation levels in GBC-SD and RBE cells treated with CDDP alone, CDCA alone and CDDP/CDCA combination for 24 h.